“I think [MRI-guided transurethral ultrasound ablation] is a potentially great option for patients who opt for either whole- or partial-gland treatment,” says researcher Steven S. Raman, MD.
Myovant Sciences recently announced positive phase III trial results for its once-daily oral small molecule gonadotropin-releasing hormone antagonist relugolix, for the treatment of advanced prostate cancer.
The FDA has approved a supplemental New Drug Application or enzalutamide (XTANDI) for the treatment of patients with metastatic castration-sensitive prostate cancer.
Urologists, oncologists, and prostate cancer patients are entering a new era in prostate cancer therapy—one that is going to be genetically defined.
Leonard G. Gomella, MD, Tanya Dorff, MD, Scott Eggener, MD, and Jorge Garcia, MD, all reflect on prostate cancer treatment in 2019.
Urology Times asked Maha H. Hussain, MD: How will the advent of PARP inhibitors change the management of advanced prostate cancer?
"The relevant professional associations in the field of medicine and/or urology must do their part to inform and educate their members about the appropriate use of finasteride and PSA to eliminate avoidable morbidity and mortality from prostate cancer," writes Badar M. Mian, MD.
Newly diagnosed low- and high-risk prostate cancer patients seen during the same appointment by a urologist and radiation oncologist were more likely than patients in a nationwide cohort to choose evidence-based care, according to a recent study.
“There is now sufficient data to support the use of prostate MRI in all men before their initial prostate biopsy when the MRI is of sufficient quality,” says policy statement co-author Marc A. Bjurlin, DO, MSc.
Urology Times asked Scott Eggener, MD: How should urologists decide between focal therapy and active surveillance in men with low-risk prostate cancer?